Skip to main content
Erschienen in: Hepatology International 4/2011

01.12.2011 | Original Article

The dissociation between the diabetes and both Child–Pugh score and in-hospital mortality in cirrhotic patients due to hepatitis B, hepatitis C, or alcoholic

verfasst von: Yu-Wei Chen, Han-Hsiang Chen, Tsang-En Wang, Ching-Wei Chang, Chen-Wang Chang, Wei-Che Chen, Chih-Jen Wu

Erschienen in: Hepatology International | Ausgabe 4/2011

Einloggen, um Zugang zu erhalten

Abstract

Background

Up to 30% of the cirrhotic patients may clinically be classified as having diabetes. The aims of this retrospective study were to evaluate the prevalence of diabetes, its association with the severity of cirrhosis, and subsequent implication on mortality in a broad population of cirrhotic patients in Taiwan.

Methods

From January 2004 to October 2008, 4,127 cirrhotic patients were reviewed. The latest demographic data were gathered after the latest laboratory measurement in the outpatient or inpatient department. In all, 2,945 patients were included on the basis of the etiology of cirrhosis: hepatitis B, hepatitis C, hepatitis B, and hepatitis C co-infection, or alcoholics.

Results

The observed cases of diabetes were significantly higher in cirrhotic patients than general population. Neither the Child–Pugh score (odds ratio = 0.99, p = 0.527) nor the model for end-stage liver disease score (MELD) (odds ratio = 1.00, p = 0.352) was associated with diabetes. The presence of diabetes was dissociated with renal function by means of serum creatinine (β = −0.01, p = 0.604) or estimated glomerular filtration rate (eGFR) (β = −0.02, p = 0.233), or in-hospital mortality (odds ratio = 1.08, p = 0.362).

Conclusion

The prevalence of diabetes was higher in cirrhotic patients in Taiwan. The prevalence of diabetes was dissociated with Child–Pugh or MELD score. The diagnosis of diabetes did not affect the renal function or in-hospital mortality in cirrhotic patients. Since the clinical outcomes of diabetes were different from cirrhotic patients to general population, it is unclear whether the treatment of diabetes and improved glycemic control will benefit cirrhotic patients.
Literatur
1.
Zurück zum Zitat Garcia-Compean D, Jaquez-Quintana JO, Gonzalez-Gonzalez JA, et al. Liver cirrhosis and diabetes: risk factors, pathophysiology, clinical implications and management. World J Gastroenterol 2009;15(3):280–288PubMedCrossRef Garcia-Compean D, Jaquez-Quintana JO, Gonzalez-Gonzalez JA, et al. Liver cirrhosis and diabetes: risk factors, pathophysiology, clinical implications and management. World J Gastroenterol 2009;15(3):280–288PubMedCrossRef
2.
Zurück zum Zitat Postic C, Dentin R, Girard J. Role of the liver in the control of carbohydrate and lipid homeostasis. Diabetes Metab 2004;30(5):398–408PubMedCrossRef Postic C, Dentin R, Girard J. Role of the liver in the control of carbohydrate and lipid homeostasis. Diabetes Metab 2004;30(5):398–408PubMedCrossRef
3.
Zurück zum Zitat Tolman KG, Fonseca V, Dalpiaz A, et al. Spectrum of liver disease in type 2 diabetes and management of patients with diabetes and liver disease. Diabetes Care 2007;30(3):734–743PubMedCrossRef Tolman KG, Fonseca V, Dalpiaz A, et al. Spectrum of liver disease in type 2 diabetes and management of patients with diabetes and liver disease. Diabetes Care 2007;30(3):734–743PubMedCrossRef
4.
Zurück zum Zitat Megyesi C, Samols E, Marks V. Glucose tolerance and diabetes in chronic liver disease. Lancet 1967;2(7525):1051–1056PubMedCrossRef Megyesi C, Samols E, Marks V. Glucose tolerance and diabetes in chronic liver disease. Lancet 1967;2(7525):1051–1056PubMedCrossRef
5.
Zurück zum Zitat Perseghin G, Mazzaferro V, Sereni LP, et al. Contribution of reduced insulin sensitivity and secretion to the pathogenesis of hepatogenous diabetes: effect of liver transplantation. Hepatol 2000;31(3):694–703CrossRef Perseghin G, Mazzaferro V, Sereni LP, et al. Contribution of reduced insulin sensitivity and secretion to the pathogenesis of hepatogenous diabetes: effect of liver transplantation. Hepatol 2000;31(3):694–703CrossRef
6.
Zurück zum Zitat Kawaguchi T, Yoshida T, Harada M, et al. Hepatitis C virus down-regulates insulin receptor substrates 1 and 2 through up-regulation of suppressor of cytokine signaling 3. Am J Pathol 2004;165(5):1499–1508PubMedCrossRef Kawaguchi T, Yoshida T, Harada M, et al. Hepatitis C virus down-regulates insulin receptor substrates 1 and 2 through up-regulation of suppressor of cytokine signaling 3. Am J Pathol 2004;165(5):1499–1508PubMedCrossRef
7.
Zurück zum Zitat García-Compean D, Jaquez-Quintana JO, Maldonado-Garza H. Hepatogenous diabetes. Current views of an ancient problem. Ann Hepatol 2009;8(1):13–20PubMed García-Compean D, Jaquez-Quintana JO, Maldonado-Garza H. Hepatogenous diabetes. Current views of an ancient problem. Ann Hepatol 2009;8(1):13–20PubMed
8.
Zurück zum Zitat Wei JN, Chuang LM, Lin RS, et al. Prevalence and hospitalization rates of diabetes mellitus in Taiwan, 1996–2000. Taiwan J Public Health 2002;21(3):173–180 Wei JN, Chuang LM, Lin RS, et al. Prevalence and hospitalization rates of diabetes mellitus in Taiwan, 1996–2000. Taiwan J Public Health 2002;21(3):173–180
9.
Zurück zum Zitat National Diabetes Data Group. Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. National Diabetes Data Group. Diabetes 1979;28(12):1039–1057. National Diabetes Data Group. Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. National Diabetes Data Group. Diabetes 1979;28(12):1039–1057.
10.
Zurück zum Zitat American Diabetes Association. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 2003;26(Suppl 1):S5–S20 American Diabetes Association. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 2003;26(Suppl 1):S5–S20
11.
Zurück zum Zitat National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002;39(2 Suppl 1):S1–S266 National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002;39(2 Suppl 1):S1–S266
12.
Zurück zum Zitat US Department of Health and Human Services. Trends in the prevalence and prevalence of self-reported diabetes mellitus—United States, 1980–1994. MMWR Morb Mortal Wkly Rep 1997;46:1014–1018 US Department of Health and Human Services. Trends in the prevalence and prevalence of self-reported diabetes mellitus—United States, 1980–1994. MMWR Morb Mortal Wkly Rep 1997;46:1014–1018
13.
Zurück zum Zitat Reaven GM. Pathophysiology of insulin resistance in human disease. Physiol Rev 1995;75(3):473–486PubMed Reaven GM. Pathophysiology of insulin resistance in human disease. Physiol Rev 1995;75(3):473–486PubMed
14.
Zurück zum Zitat Knobler H, Schihmanter R, Zifroni A, et al. Increased risk of type 2 diabetes in noncirrhotic patients with chronic hepatitis C virus infection. Mayo Clin Proc 2000;75(4):355–359PubMedCrossRef Knobler H, Schihmanter R, Zifroni A, et al. Increased risk of type 2 diabetes in noncirrhotic patients with chronic hepatitis C virus infection. Mayo Clin Proc 2000;75(4):355–359PubMedCrossRef
15.
Zurück zum Zitat Fraser GM, Harman I, Meller N, et al. Diabetes mellitus is associated with chronic hepatitis C but not chronic hepatitis B infection. Isr J Med Sci 1996;32(7):526–530PubMed Fraser GM, Harman I, Meller N, et al. Diabetes mellitus is associated with chronic hepatitis C but not chronic hepatitis B infection. Isr J Med Sci 1996;32(7):526–530PubMed
16.
Zurück zum Zitat Papatheodoridis GV, Chrysanthos N, Savvas S, et al. Diabetes mellitus in chronic hepatitis B and C: Prevalence and potential association with the extent of liver fibrosis. J Viral Hepatol 2006;13(5):303–310CrossRef Papatheodoridis GV, Chrysanthos N, Savvas S, et al. Diabetes mellitus in chronic hepatitis B and C: Prevalence and potential association with the extent of liver fibrosis. J Viral Hepatol 2006;13(5):303–310CrossRef
17.
Zurück zum Zitat Deschenes M, Somberg KA. Effect of transjugular intrahepatic portosystemic shunt (TIPS) on glycemic control in cirrhotic patients with diabetes mellitus. Am J Gastroenterol 1998;93(3):483PubMedCrossRef Deschenes M, Somberg KA. Effect of transjugular intrahepatic portosystemic shunt (TIPS) on glycemic control in cirrhotic patients with diabetes mellitus. Am J Gastroenterol 1998;93(3):483PubMedCrossRef
18.
Zurück zum Zitat Zein NN, Abdulkarim AS, Wiesner RH, et al. Prevalence of diabetes mellitus in patients with end-stage liver cirrhosis due to hepatitis C, alcohol, or cholestatic disease. J Hepatol 2000;32(2):209–217PubMedCrossRef Zein NN, Abdulkarim AS, Wiesner RH, et al. Prevalence of diabetes mellitus in patients with end-stage liver cirrhosis due to hepatitis C, alcohol, or cholestatic disease. J Hepatol 2000;32(2):209–217PubMedCrossRef
19.
Zurück zum Zitat Chen YW, Wu CJ, Chang CW, et al. Renal Function in Patients with Liver Cirrhosis. Nephron Clin Pract 2011;118(2):195–203CrossRef Chen YW, Wu CJ, Chang CW, et al. Renal Function in Patients with Liver Cirrhosis. Nephron Clin Pract 2011;118(2):195–203CrossRef
20.
Zurück zum Zitat Adams LA, Sanderson S, Lindor KD, et al. The histological course of nonalcoholic fatty liver disease: A longitudinal study of 103 patients with sequential liver biopsies. J Hepatol 2005;42(1):132–138PubMedCrossRef Adams LA, Sanderson S, Lindor KD, et al. The histological course of nonalcoholic fatty liver disease: A longitudinal study of 103 patients with sequential liver biopsies. J Hepatol 2005;42(1):132–138PubMedCrossRef
21.
Zurück zum Zitat Taura N, Ichikawa T, Hamasaki K, et al. Association between liver fibrosis and insulin sensitivity in chronic hepatitis C patients. Am J Gastroenterol 2006;101(12):2752–2759PubMedCrossRef Taura N, Ichikawa T, Hamasaki K, et al. Association between liver fibrosis and insulin sensitivity in chronic hepatitis C patients. Am J Gastroenterol 2006;101(12):2752–2759PubMedCrossRef
22.
Zurück zum Zitat Wiesner RH, McDiarmid SV, Kamath PS, et al. MELD and PELD: Application of survival models to liver allocation. Liver Transpl 2001;7(7):567–580PubMedCrossRef Wiesner RH, McDiarmid SV, Kamath PS, et al. MELD and PELD: Application of survival models to liver allocation. Liver Transpl 2001;7(7):567–580PubMedCrossRef
23.
Zurück zum Zitat Holstein A, Hinze S, Thiessen E, et al. Clinical implications of hepatogenous diabetes in liver cirrhosis. J Gastroenterol Hepatol 2002;17(6):677–681PubMedCrossRef Holstein A, Hinze S, Thiessen E, et al. Clinical implications of hepatogenous diabetes in liver cirrhosis. J Gastroenterol Hepatol 2002;17(6):677–681PubMedCrossRef
24.
Zurück zum Zitat Chen YW, Wu CJ, Wang TE, et al. The mortality survey of elderly cirrhotic patients in Taiwan—a single center experience. J Am Geriatr Soc 2010;58(11):2230–2232PubMedCrossRef Chen YW, Wu CJ, Wang TE, et al. The mortality survey of elderly cirrhotic patients in Taiwan—a single center experience. J Am Geriatr Soc 2010;58(11):2230–2232PubMedCrossRef
25.
Zurück zum Zitat Trombetta M, Spiazzi G, Zoppini G, et al. Review article: Type 2 diabetes and chronic liver disease in the Verona diabetes study. Aliment Pharmacol Ther 2005;22(Suppl. 2):24–27PubMedCrossRef Trombetta M, Spiazzi G, Zoppini G, et al. Review article: Type 2 diabetes and chronic liver disease in the Verona diabetes study. Aliment Pharmacol Ther 2005;22(Suppl. 2):24–27PubMedCrossRef
26.
Zurück zum Zitat Bianchi G, Marchesini G, Zoli M, et al. Prognostic significance of diabetes in patients with cirrhosis. Hepatol 1994;20(1):119–125 Bianchi G, Marchesini G, Zoli M, et al. Prognostic significance of diabetes in patients with cirrhosis. Hepatol 1994;20(1):119–125
27.
Zurück zum Zitat Yuan JM, Govindarajan S, Arakawa K, et al. Synergism of alcohol, diabetes, and viral hepatitis on the risk of hepatocellular carcinoma in blacks and whites in the U.S. Cancer 2004;101(5):1009–1017PubMedCrossRef Yuan JM, Govindarajan S, Arakawa K, et al. Synergism of alcohol, diabetes, and viral hepatitis on the risk of hepatocellular carcinoma in blacks and whites in the U.S. Cancer 2004;101(5):1009–1017PubMedCrossRef
28.
Zurück zum Zitat Kawaguchi T, Taniguchi E, Morita Y, et al. Association of exogenous insulin or sulphonylurea treatment with an increased incidence of hepatoma in patients with hepatitis C virus infection. Liver Int 2010;30(3):479–486PubMedCrossRef Kawaguchi T, Taniguchi E, Morita Y, et al. Association of exogenous insulin or sulphonylurea treatment with an increased incidence of hepatoma in patients with hepatitis C virus infection. Liver Int 2010;30(3):479–486PubMedCrossRef
29.
Zurück zum Zitat Donadon V, Balbi M, Ghersetti M, et al. Antidiabetic therapy and increased risk of hepatocellular carcinoma in chronic liver disease. World J Gastroenterol 2009;15(20):2506–2511PubMedCrossRef Donadon V, Balbi M, Ghersetti M, et al. Antidiabetic therapy and increased risk of hepatocellular carcinoma in chronic liver disease. World J Gastroenterol 2009;15(20):2506–2511PubMedCrossRef
Metadaten
Titel
The dissociation between the diabetes and both Child–Pugh score and in-hospital mortality in cirrhotic patients due to hepatitis B, hepatitis C, or alcoholic
verfasst von
Yu-Wei Chen
Han-Hsiang Chen
Tsang-En Wang
Ching-Wei Chang
Chen-Wang Chang
Wei-Che Chen
Chih-Jen Wu
Publikationsdatum
01.12.2011
Verlag
Springer-Verlag
Erschienen in
Hepatology International / Ausgabe 4/2011
Print ISSN: 1936-0533
Elektronische ISSN: 1936-0541
DOI
https://doi.org/10.1007/s12072-011-9274-y

Weitere Artikel der Ausgabe 4/2011

Hepatology International 4/2011 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

29.05.2024 Herzinfarkt Nachrichten

Bei Menschen mit Typ-2-Diabetes sind die Chancen, einen Myokardinfarkt zu überleben, in den letzten 15 Jahren deutlich gestiegen – nicht jedoch bei Betroffenen mit Typ 1.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.